Direct Impact of In-House Rapid Lung Next-Generation Sequencing on Outcomes for Patients with Cancer - European Medical Journal

Direct Impact of In-House Rapid Lung Next-Generation Sequencing on Outcomes for Patients with Cancer

Oncology

This webinar was supported by Thermo Fisher.

Our latest webinar explores precision oncology in the form of biomarkers and treatments for non-small cell lung cancer. Francesco Passiglia, Thoracic Oncologist, San Luigi Hospital, Orbassano, Turin, Italy, and Associate Professor in the Department of Oncology at the University of Turin, Italy, present on turnaround time as a barrier to precision treatment plans, and spotlight how rapid lung next-generation sequencing can combat this.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>